The Drug Enforcement Administration has proposed a 2027 national production ceiling for ibogaine of 12,002 grams. The ceiling it established for 2026, in a final order published on January 5, is 210 grams.
That is about 57 times the current figure, and the largest proportional increase among the quotas that appear in both the November notice and the January order. The notice appeared in the Federal Register on November 10 under Docket No. DEA-1730P, with proposed quotas for every other Schedule I and II controlled substance. Comments close on December 10, and a final order follows; the Administrator may hold a public hearing first.
Updated November 12, 2026: W. Bryan Hubbard, chief executive of Americans for Ibogaine, gave his assessment of the proposal after publication. His comments are carried with the passages they concern.
Of the seven psychedelic quotas tracked here, four rise and three do not move.
| Substance | 2026 established | Proposed 2027 | Change |
|---|---|---|---|
| Ibogaine | 210 g | 12,002 g | 57-fold |
| MDMA | 12,000 g | 33,296 g | +177% |
| Psilocybin | 50,000 g | 60,000 g | +20% |
| Psilocyn | 80,000 g | 93,600 g | +17% |
| DMT | 25,000 g | 25,000 g | none |
| 5-MeO-DMT | 30,000 g | 30,000 g | none |
| LSD | 1,200 g | 1,200 g | none |
Source: DEA’s proposed 2027 aggregate production quotas, Federal Register, November 10, 2026, and its established 2026 quotas, January 5, 2026. Figures are grams of anhydrous acid or base. Percentage and fold changes are Behavioral Wire’s calculations.
One note on the comparison. The notice prints only the proposed 2027 figures, with no 2026 column or percentage change, and describes its changes against “2026 proposed revised” values, a phrase it does not define. The DEA finalized adjusted 2026 values for four Schedule II quotas the same day, in a separate order that left every other 2026 quota “as previously established.” The January figures are the established 2026 quotas for these substances, and they are the baseline here.
What the agency says is behind it
The stated reason covers MDMA and ibogaine in one sentence. The higher quotas are proposed “to support manufacturing activities related to the increased level of research and clinical trials being conducted with these substances for potential treatment of conditions including post-traumatic stress disorder (PTSD) and depression.” Psilocybin and psilocyn appear nowhere in the notice except the table, so their 20 and 17 percent increases come with no explanation.
The next sentence supplies the policy link, and its verb matters: “This increase in research and clinical trials aligns with two Presidential Executive Orders.” The chain the notice asserts runs from research activity, to the manufacturing that supports it, to a higher ceiling. The orders are something that activity aligns with, not the instruction behind the number. Their text fits that reading. Executive Order 14379, on addiction treatment and recovery, never mentions psychedelics or ibogaine. Executive Order 14401, signed April 18, directs the FDA and DEA to “facilitate and establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act,” with Schedule I handling authorizations consistent with 21 U.S.C. 823, the registration provision. Neither order contains the words quota, supply or manufacturing.
W. Bryan Hubbard, chief executive of Americans for Ibogaine, a 501(c)(3) charity that advocates for medical access to ibogaine, reads the same proposal as a political result.
“The 57-fold increase in ibogaine quota demonstrates DEA’s obedience to the authority of representative democracy which has chosen to make ibogaine’s medicalization a national priority through the expeditious initiation of an FDA trial. This is exactly how government is supposed to work.”
— W. Bryan Hubbard, chief executive of Americans for Ibogaine, in comments to Behavioral Wire
That is his account of why the number moved; it is not the one the notice gives. The trial he refers to is also not in the public registry: ClinicalTrials.gov lists several ibogaine studies in opioid use disorder, none of them described as a federal, multi-state or multi-tribal trial.
How a production quota works
An aggregate production quota is an annual national total: in the notice’s words, the quantities “to be manufactured in the United States in 2027 to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks.” The ceiling is where a sequence starts, not where it ends. Keep these apart:
- The national ceiling. The figure in this notice, shared across every registered manufacturer of the substance.
- Registration. A company must be registered with the DEA as a bulk manufacturer or an importer for that specific drug code before it may make or bring in any of it.
- An individual quota. A quota the DEA issues to a registered manufacturer for the year, within the ceiling. Neither the notice nor the registration filings list any.
- An import permit. Separate again: importing a Schedule I substance takes a registered importer and a DEA permit.
- Production. What is actually made. The notice does not report it for ibogaine.
A larger ceiling removes a constraint at the first layer and establishes nothing about the others. The notice says nothing about manufacturing or import capacity, clinical trial supply or the approval of any ibogaine product, does not translate 12,002 grams into doses, participants or trials, and does not say whether 210 grams limited anyone in 2026. The FDA has approved no ibogaine product for any use.
Hubbard puts the weight differently. In his account supply is the governing constraint, not one layer of several.
“Clinical research trials cannot occur at scale without adequate ibogaine supply. Ensuring that supply is adequate to resource clinical trial demands is, by far, the single most significant factor for the achievement of progress. As supply navigates the system, requirements which become barriers to progress need to be readily identified and efficiently remedied.”
— W. Bryan Hubbard, chief executive of Americans for Ibogaine, in comments to Behavioral Wire
He does not dismiss the other authorizations; his framing is that they should be identified and cleared once supply exists. That is a claim about sequence and priority, not about what the authorizations require.
One of the seven factors the Administrator weighs is projected demand “as indicated by procurement quotas requested.” The notice cites requests elsewhere: it lowers acetyl fentanyl and heroin “based on the decline in the amount of quota requested.” For ibogaine and MDMA it cites research and clinical trials, and does not say whether requests were received, how many, or from whom.
The ibogaine registration file
The public file for ibogaine is mostly applications. Benuvia Operations of Round Rock, Texas applied on April 22 to be a bulk manufacturer and on August 11 to be an importer, for “internal research and dosage formulation development” and “internal research and development toward the bulk manufacture of API for future clinical trials,” respectively. Groff Health of York, Pennsylvania applied on September 3 to make ibogaine, MDMA, psilocybin and psilocyn “for internal use and for sale to its customers”; objections are due December 18. The Federal Register does not report whether anyone objected to Benuvia’s import application, which was open until October 28.
Psyence BioMed, whose Texas subsidiary contracted Benuvia in October, said in its release that, according to Benuvia, the manufacturer holds approximately half of the national ibogaine quota, a figure the release said was not independently verified. Against 210 grams that would be about 105 grams. The significance of any claimed share would change substantially if the national ceiling rose to 12,002 grams. Psyence’s U.S. program was built around the registration and permit layers, not around the ceiling.
The same issue, a different kind of evidence
The same Federal Register issue carried a DEA order raising four Schedule II quotas by about 19 to 40 percent under 21 U.S.C. 826(h). Its basis was stated at length: requests from registered manufacturers, none named, dated July 24 to August 24; shortage reports on the FDA list; and an FDA prediction that 2026 domestic need for amphetamines would rise about 24 percent. The statute gave the DEA 30 days, and the agency said that clock left no room for a comment period.
Part of the contrast is the instrument. A shortage adjustment answers specific requests, and an annual proposal weighs seven factors across every substance. Even so, the proposal’s disclosure for ibogaine is one sentence it shares with MDMA, and for psilocybin and psilocyn there is none.
The constraints outside the notice
Until a final order, 12,002 grams is a proposal and 210 grams remains the operative ceiling; the final numbers may land at, above or below it. The quota is the one constraint that sits in a single public notice. The rest happens registrant by registrant and mostly outside the public record: a granted registration, an individual quota inside the ceiling, an import permit, and an investigational new drug application with chemistry and manufacturing data behind it. For ibogaine, none of those is yet confirmed in the public record, which shows applications and a company’s unverified account of its quota.
Hubbard sets the same test on a 2027 clock.
“Reality must be measured by reality. If a quota adjustment doesn’t yield a substantial increase in ibogaine research and development activity during 2027 - with the primary focus of supply being the federal/multi-state/multi-tribal trial for OUD - then we’ll know the adjustment alone was not enough to drive progress. If progress doesn’t flow from quota, then we’ll need to demand answers from DEA.”
— W. Bryan Hubbard, chief executive of Americans for Ibogaine, in comments to Behavioral Wire
The two readings converge there: what matters next is 2027 activity, not the 2027 number.
A 57-fold proposed ceiling is a statement about what the DEA proposes to allow. It is not yet a statement about what anyone is able to make.